T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

Pioneering a new frontier in antibiotic stewardship to combat the growing threat of antimicrobial resistance LEXINGTON, Mass. and SCHENECTADY, N.Y. , Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic